Cracow

• Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) Ended recruitment
  2023-505495-30-00 5 2019-02-01 Immunoglobulin A Nephropathy (IgAN)
• MK-3475 (SCH 9000475) as neoadjuvant and adjuvant therapy in Stage III-IVA resectable LA HNSCC (Locoregionally Advanced Head and Neck Squamo … Ended recruitment
  2022-500254-41-00 5 2018-12-13 Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamou
• A trial to learn how well durvalumab and chemotherapy with or without tremelimumab work in adults with advanced cancer of the bladder or uri … Ended recruitment
  2024-510976-19-00 5 2018-11-30 Patients with Unresectable Locally Advanced or Metastatic Urothelial C
• Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma Ended recruitment
  2022-501966-23-00 5 2018-09-11 Resected High-Risk Stage II Melanoma
• Extended Access of Momelotinib for Subjects with Myelofibrosis Ended recruitment
  2023-508018-41-00 4 2018-07-27 Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential
• A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease Ended recruitment
  2023-504736-18-00 10 2018-07-26 Moderately to Severely Active Crohn's Disease
• Research study to evaluate the experimental drug ferumoxytol, to see how well it works for children with chronic kidney disease (CKD) and ir … Ended recruitment
  2024-516263-92-00 5 2018-06-25 Iron Deficiency Anemia (IDA) in Pediatric Subjects with Chronic Kidney
• A Phase 3 Study of Zanubrutinib (BGB-3111) Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocyt … Ended recruitment
  2023-509976-40-00 5 2018-05-28 Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
• A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended recruitment
  2023-504802-12-00 7 2018-05-16 Lymphoma of B-cell origin
• A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis Ended recruitment
  2023-506429-13-00 5 2018-05-02 Progressive multiple sclerosis (PMS)
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended recruitment
  2024-515499-12-00 5 2017-10-02 Acute lymphoblastic leukemia
• A Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small C … Ended recruitment
  2023-507500-31-00 10 2017-08-22 Advanced or metastatic Non-small cell lung cancer (NSCLC)
• A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Comple … Ended recruitment
  2023-504951-29-00 5 2017-07-27 Chron's Disease
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination wi … Ended recruitment
  2023-509354-58-00 5 2017-07-14 Mantle Cell Lymphoma
• A Clinical trial to compare Acalabrutinib (ACP-196) versus investigator's choice standard treatment with Bendamustine/Rituximab or Idelalisi … Ended recruitment
  2023-509359-15-00 5 2017-03-08 Relapsed or Refractory Chronic Lymphocytic Leukemia
• A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson’s Disease (BeyoND) Ended recruitment
  2024-513548-27-00 4 2016-10-05 Parkinson's disease
• A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab ( … Ended recruitment
  2023-509353-31-00 2 2016-09-05 Mantle Cell Lymphoma
• A Study with an active treatment to Assess the Long-term Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Al … Ended recruitment
  2024-513962-20-00 5 2016-07-14 Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficiency
• A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Meth … Ended recruitment
  2022-501017-31-00 5 2016-05-10 Rheumatoid arthritis
• Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD). Ended recruitment
  2023-509425-53-00 5 2015-11-09 Atopic Dermatitis
• A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High R … Ended recruitment
  2023-509347-27-00 5 2015-09-30 High Risk Chronic Lymphocytic Leukaemia
• A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obi … Ended recruitment
  2023-509348-84-00 5 2015-04-27 Chronic Lymphocytic Leukemia
• A Controlled Study with an active treatment and a Placebo to Assess the Efficacy and Safety of Weekly Intravenous Product in Subjects with P … Ended recruitment
  2023-510030-83-00 5 2014-01-29 Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficiency
• A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study Ended recruitment
  2023-503803-27-00 5 2013-10-25 B-cell non-Hodgkin's lymphoma and cGVHD

Showing 745–768 of 1,081 trials